Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

Provides update on business and product pipeline

BOTHELL, WA and VANCOUVER, Nov. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer, today reported unaudited financial results for the third quarter and nine months ended September 30, 2008.

Third Quarter 2008 Financial Results

On August 21, 2008, Sonus Pharmaceuticals, Inc. ("Sonus") and OncoGenex Technologies Inc. ("OncoGenex Technologies") completed a reverse takeover. In accordance with generally accepted accounting principles, OncoGenex Technologies is deemed to have acquired Sonus from an accounting perspective. Therefore, the consolidated results of operations of the Company include the results of OncoGenex Technologies for the third quarter and nine month periods that ended September 30, 2008 and 2007 respectively and the results of OncoGenex Pharmaceuticals, Inc. following the completion of the transaction with Sonus.

Research and development expenses for the third quarter and nine months ended September 30, 2008, were $1.6 million and $3.6 million respectively, compared with $1.1 million and $3.1 million respectively in 2007. The increases in 2008 were primarily due to costs associated with the development of OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus.

General and administrative expenses for the third quarter and nine months ended September 30, 2008, were $1.0 million and $2.2 million respectively, compared with $0.6 million and $2.7 million respectively in 2007. The increase for the third quarter of 2008 wa
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
(Date:4/23/2015)... April 23, 2015 /CNW/ - A new and innovative ... from North America,s largest ... won Silver in the "Sustainability, service" category of ... Brandcheck "Competitor Comparison" is a service that scores ... and Global peers. This benchmarking process shows clients ...
(Date:4/23/2015)... D.C. (PRWEB) April 23, 2015 ... D.C. region on April 4-17 as part of ... marks the fourth group of biotechnology startups to ... of Nizhny Novgorod (UNN) and the University of ... deepen ties between their respective universities in the ...
(Date:4/23/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology and medical device industries, with ... the United States , today announced that ... of 2015 after the New York Stock Exchange closes ... morning, May 14, 2015 Shanghai time). The earnings release ...
Breaking Biology Technology:Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... Massachusetts, HARRISBURG, Pa., July 23 Pennsylvania,s,efforts ... have,made it the number one state in the ... Edward G. Rendell said today., "We have ... in,biotech," Governor Rendell said of the overall biotechnology ...
... ROCKVILLE, Md., July 23 Human Genome,Sciences, Inc. (Nasdaq: ... a,conference call to discuss its financial results for the ... be disclosed on Wednesday, July 30,2008, after the capital ... The conference call will be hosted by senior management ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) announced ... N. Doshi and the appointment as a Director of ... President -,Business Strategies of the Company, effective July 22, ... President of Business,Strategies in July 2007, Mr. Singh served ...
Cached Biology Technology:Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study 2Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study 3Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results 2Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... in Efficient and Sustainable Global Logistics Operations) is aiming ... the efficiency of intermodal loading systems and the boosting ... 29 European organisations with experience in the logistics sector ... totalling 17,000,000 and a duration of three and a ...
... MD The Federation of American Societies for Experimental ... National Institutes of Health (NIH) funding trends highlighting the ... support critical research. The FASEB analysis follows a May ... Collins, MD, PhD, who testified that the $1.6 billion ...
... Bethesda, MD (May 17, 2013) Illustrating a ... the American Gastroenterological Association (AGA) Research Foundation ... Future Student Research Fellowship Award recipients. Supported by ... Kidney Diseases (NIDDK), this new award helps underrepresented ...
Cached Biology News:New logistics services that will cut energy consumption and CO2 emissions 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
Request Info...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: